Revenue: As of FY2025 Q2, the actual value is USD 16.72 M.EPS: As of FY2025 Q2, the actual value is USD -0.12.<h3>Segment Revenue</h3><ul><li>Total Revenues: $16.72 million for the three months ended June 30, 2025, compared to $18.65 million for the same period in 2024, representing a decrease of 10.4%.</li><li>Services Revenue: $4.86 million for the three months ended June 30, 2025, compared to $5.58 million for the same period in 2024.</li><li>Wellness Revenue: $11.03 million for the three months ended June 30, 2025, compared to $11.55 million for the same period in 2024.</li><li>Pet Food &amp; Treats Revenue: $0.84 million for the three months ended June 30, 2025, compared to $1.52 million for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $6.15 million for the three months ended June 30, 2025, compared to $2.25 million for the same period in 2024, representing an increase of 173%.</li><li>Total Costs and Expenses: $21.33 million for the three months ended June 30, 2025, compared to $19.30 million for the same period in 2024, representing an increase of 10.5%.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $1.25 million for the six months ended June 30, 2025, compared to $2.02 million for the same period in 2024.</li><li>Net Cash Used in Investing Activities: $0.60 million for the six months ended June 30, 2025, compared to $0.99 million for the same period in 2024.</li><li>Net Cash Used in Financing Activities: $1.10 million for the six months ended June 30, 2025, compared to $6.08 million for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is undergoing Chapter 11 bankruptcy proceedings and has filed a joint prepackaged plan of reorganization. The plan includes a restructuring support agreement with a debtor-in-possession loan facility of up to $6.5 million and an exit facility of up to $18.3 million.</li><li>Non-Core Business: The company sold its prescription management and digital e-prescribing software, Furscription, for $5.0 million, with $3.4 million of the proceeds used to pay down existing debt.</li><li>Priority: The company is focused on restructuring and emerging from Chapter 11, with plans subject to approval by the Bankruptcy Court.</li></ul>

WAG GROUP CO | 10-Q: FY2025 Q2 Revenue: USD 16.72 M